**Initiating a New IRB Protocol**

Is your study a prospective clinical research study? Has your study been created in Velos eResearch by the Office of Clinical Trials? If yes to 1 and no to 2, do not proceed and email your study documents to clinicaltrials@umc.edu

If yes and your study has already been created in Velos eResearch by the Office of Clinical Trials, **skip to step 4. Please work with your OCT Project Manager closely.**

If no to both, proceed to **step 1.**

1. Log into Velos eResearch ([www.ummcprod.veloseresearch.com](http://www.ummcprod.veloseresearch.com)) using your UMMC credentials
2. Click on Protocols – New Protocol

![Image of the Velos eResearch interface with highlighted options]

3. **Complete the Initial Details Tab.**
   a. **Study Details**
      - Study Number: *auto-generated after saving*
      - Title: Enter title of project
      - Study Entered By: *auto-generated*
      - Principal Investigator: Select user
• If Other: Enter Co-PI name *(if applicable)*
• Study Contact: Enter person who should communicate with the IRB and other regulatory/administrative offices
• PI is Major Author/Initiator of Study: Click if PI will be listed as major author on any publications or developed the protocol
• CTRP Reportable: Click if trial is supported by the National Cancer Institute (NCI)
• Primary Objective: Enter major objective of study
• Summary: Enter lay summary [*8th grade reading level*]
• NCT Number: Enter National Clinical Trial Number
• Primary Purpose: Select primary purpose of study
• Agent/Device: Enter agent/device name or number
• Department: Select PI’s departments
• Therapeutic Area: Select PI’s division/study area
• Disease Site: Select disease site(s) [Optional]
• Maximum Accrual: Enter global accrual size for entire study. Once study is saved, the local sample size can be entered.
• Study Duration: Enter duration. Can be in days, weeks, months, or years
• Duration: Select Duration Period
• Estimated Begin Date: Select date study is estimated to begin
• CCSG Data Table 4 Reportable: [For Cancer studies only]
• Phase: Select phase
• Study Source: Select study source [*based off sponsor*]
• Study Scope: Select scope
• Clinical Research Category: Select category
• Linked to: [*only for use by OCT*]
• Blinding: Select blinding option
• Randomization: Select randomization option
• Sponsor Type: Select sponsor type
• Sponsor Protocol Number: Enter protocol number as provided by sponsor
• Primary Contact: Enter name and email of sponsor’s primary contact
• NIH Grant Information: If study is funded by NIH, provide grant/contract information
• Keywords: Insert all keywords separated by commas. Any keywords listed will be searchable using the top search bar in the Velos system.

b. IND/IDE Information
• If study includes the use of an IND/IDE, enter relevant information.

c. More Details
• UMMC IRB Number: [only for use by the OCT]
• External IRB Number: If study is reviewed by an external IRB, enter the IRB number
• External IRB Name: Enter external IRB name
• Coordinating Group Number: If study is funded by a cooperative group, enter the group number
• NCI Number: If study is funded by NCI, enter NCI number [Cancer studies only]
• SWOG Number: If study is funded by SWOG, enter SWOG number [Cancer studies only]
• NRG Number: If study is funded by NRG, enter NRG number [Cancer studies only]
• Alliance Number: If study is funded by Alliance, enter NRG number [Cancer studies only]
• Short Title: Enter any short titles associated with the study [e.g., SMART]
• Prime Sponsor Name: Select Prime Sponsor. A prime sponsor is defined as the originating source of the project funding.
• Prime Sponsor Type: Select Prime Sponsor Type
- Sponsor Name: Select Direct Sponsor. A *direct sponsor is defined as the agency or entity from which UMMC directly receives project funding.*
- Inpatient Study: Select if study participants will have inpatient status
- Centers/Institutes: Select Centers/Institutes the trial should be associated with
- OCT Study: *[for OCT use only]*
- Protocol requires informed consent?: Select if protocol requires informed consent
- Send Study to Investigational Drug Service: *[For OCT use only]*
- Click Save.
- Click on Local Sample Size under the Study Details Tab
a) Enter Local Sample Size for UMMC.
b) Enter e-Signature
c) Click Submit

4. **Attachments Tab**
   a. Upload any attachments relevant to your study/IRB review in the applicable category
   b. Click Add New Document
      • For description, please use the following naming convention: Type of Document_Version_Date_Status (e.g., Protocol_V1_12082020_FINAL)
      • Enter e-signature
      • Click submit
      • Repeat for each set of five documents
5. Study Team
a. Click on the Clipboard icon in the top right corner

b. Navigate to Study Team Tab
c. Click on Add/Edit Study Team Member
d. Search for study team member and click checkbox to add.
e. Repeat for all study team members
f. Select roles for each member
g. Click on the icon. Input the individual’s CITI training expiration date (if not pre-populated in their profile – hover over the arrow icon) and whether they are eligible to give informed consent.

h. Click Submit
i. Click on the Folder icon in the top right corner

6. Click on Submission Checklist icon in the Workflow Panel
a. Complete the Submission Checklist
b. Select Completed in Form Status
c. Enter e-Signature
d. Click Submit

7. Check and Submit Tab
   a. Click on Check and Submit
b. Ensure all three sections have a ☑️ icon

c. Using the IRB Submission Table below, choose the applicable IRB board for which to send the study by checking the applicable box in the far right column

d. Enter e-signature

e. Click Submit

Congratulations! Your IRB protocol has now been submitted to the Human Research Office for review.

Video: https://youtu.be/CsjrAsdWC54
<table>
<thead>
<tr>
<th>If your protocol is submitted between:</th>
<th>It will be reviewed by:</th>
<th>On:</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/24/2020-01/13/2021</td>
<td>IRB1</td>
<td>01/26/2021</td>
</tr>
<tr>
<td>01/14/2021-01/27/2021</td>
<td>IRB2</td>
<td>02/09/2021</td>
</tr>
<tr>
<td>01/28/2021-02/10/2021</td>
<td>IRB1</td>
<td>02/23/2021</td>
</tr>
<tr>
<td>02/11/2021-02/24/2021</td>
<td>IRB2</td>
<td>03/09/2021</td>
</tr>
<tr>
<td>02/25/2021-03/10/2021</td>
<td>IRB1</td>
<td>03/23/2021</td>
</tr>
<tr>
<td>03/11/2021-03/24/2021</td>
<td>IRB2</td>
<td>04/13/2021</td>
</tr>
<tr>
<td>03/25/2021-04/14/2021</td>
<td>IRB1</td>
<td>04/27/2021</td>
</tr>
<tr>
<td>04/15/2021-04/28/2021</td>
<td>IRB2</td>
<td>05/11/2021</td>
</tr>
<tr>
<td>04/29/2021-05/12/2021</td>
<td>IRB1</td>
<td>05/25/2021</td>
</tr>
<tr>
<td>05/13/2021-05/26/2021</td>
<td>IRB2</td>
<td>06/08/2021</td>
</tr>
<tr>
<td>05/27/2021-06/09/2021</td>
<td>IRB1</td>
<td>06/22/2021</td>
</tr>
<tr>
<td>06/10/2021-06/23/2021</td>
<td>IRB2</td>
<td>07/13/2021</td>
</tr>
<tr>
<td>06/24/2021-07/14/2021</td>
<td>IRB1</td>
<td>07/27/2021</td>
</tr>
<tr>
<td>07/15/2021-07/28/2021</td>
<td>IRB2</td>
<td>08/10/2021</td>
</tr>
<tr>
<td>07/29/2021-08/11/2021</td>
<td>IRB1</td>
<td>08/26/2021</td>
</tr>
<tr>
<td>08/12/2021-08/25/2021</td>
<td>IRB2</td>
<td>09/14/2021</td>
</tr>
<tr>
<td>08/26/2021-09/15/2021</td>
<td>IRB1</td>
<td>09/28/2021</td>
</tr>
<tr>
<td>09/16/2021-09/29/2021</td>
<td>IRB2</td>
<td>10/12/2021</td>
</tr>
<tr>
<td>09/30/2021-10/13/2021</td>
<td>IRB1</td>
<td>10/26/2021</td>
</tr>
<tr>
<td>10/14/2021-10/27/2021</td>
<td>IRB2</td>
<td>11/09/2021</td>
</tr>
<tr>
<td>10/28/2021-11/10/2021</td>
<td>IRB1</td>
<td>11/23/2021</td>
</tr>
<tr>
<td>11/11/2021-11/24/2021</td>
<td>IRB2</td>
<td>12/14/2021</td>
</tr>
<tr>
<td>11/25/2021-12/15/2021</td>
<td>IRB1</td>
<td>12/28/2021</td>
</tr>
</tbody>
</table>